Kyntra Bio receives final $4M holdback from AstraZeneca for China ops sale

KYNTRA BIO, INC.

Received $4.0M from AstraZeneca, satisfying final holdback under February 2025 share purchase agreement.
Total consideration for sale of China operations was ~$220M ($85M enterprise value + ~$135M net cash).
Previously received $6.0M holdback plus $0.4M net cash adjustment payment in November 2025.
With this payment, all owed amounts under the Share Purchase Agreement have been collected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.